A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

No abstract is available for this paper.

• Publication year

  1991

• Venue

  British Journal of Psychiatry

• Publication date

  1991-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.159.3.394PMID 1835664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers

  2004cited by this paper
• Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

  2004cited by this paper
• Fluoxetine-induced sexual dysfunction.

  1990cited by this paper
• A review of the metabolism and pharmacokinetics of paroxetine in man

  1989cited by this paper
• The clinical pharmacology of paroxetine in healthy subjects

  1989cited by this paper
• Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

  1989cited by this paper
• Paroxetine in the treatment of depression: a comparison with imipramine and placebo

  1989cited by this paper
• Psychiatric care of refugees exposed to organized violence

  1989cited by this paper
• An overview of the animal pharmacology of paroxetine

  1989cited by this paper
• The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol

  1989cited by this paper
• The effect of paroxetine on the quantitative EEG

  1989cited by this paper
• What destroys our restraints against suicide

  1988cited by this paper
• Sertraline: a new antidepressant.

  1988cited by this paper
• Relation between yawning behavior and central serotonergic neuronal system in rats

  1987cited by this paper
• Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor

  1987cited by this paper
• The effect of selective 5‐hydroxytryptamine uptake inhibitors on 5‐methoxy‐N,N‐dimethyltryptamine‐induced ejaculation in the rat

  1986cited by this paper
• Stimulation of spinal serotonergic receptors facilitates seminal emission and suppresses penile erectile reflexes.

  1985cited by this paper
• Effects of psychotropic agents on primary depression

  1981cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF‐REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

  1969cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis

  2024cites this paper
• β-Cyclodextrin/Zn–Fe layered double hydroxides/graphitic carbon nitride nanomaterials based potentiometric sensor for paroxetine determination in environmental water samples

  2024cites this paper
• Assessment of psychotropic medications prescribing pattern in Gebretsadik Shawo General Hospital, South West Ethiopia

  2023cites this paper
• Individual and common patterns in the order of symptom improvement during outpatient treatment for major depression.

  2021cites this paper
• Fish Oil, but Not Olive Oil, Ameliorates Depressive-Like Behavior and Gut Microbiota Dysbiosis in Rats under Chronic Mild Stress

  2019cites this paper
• Assessment of health-related quality of life , patient-reported mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression

  2018cites this paper
• Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis

  2017cites this paper
• Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants

  2017cites this paper
• Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression

  2017cites this paper
• Melhora precoce e resposta no tratamento antidepressivo

  2017influential citation
• Meta-analysis: Risk of dry mouth with second generation antidepressants

  2017cites this paper
• A comparative study of solid and liquid inner contact paroxetine hydrochloride ion-selective electrode membranes

  2015cites this paper
• Antidepressants and Gastrointestinal Symptoms in the General Dutch Adult Population

  2014cites this paper
• Construction and Performance Characterization of Ion‐Selective Electrodes for Potentiometric Determination of Paroxetine Hydrochloride in Pharmaceutical Preparations and Biological Fluids

  2014cites this paper
• Paroxetine versus other anti-depressive agents for depression.

  2014cites this paper
• Prevalence and determinants of gastrointestinal symptoms in the Dutch community

  2013cites this paper
• A Review of its Pharmacology and Therapeutic Potential in the Management of Panic Disorder

  2012cites this paper
• Paroxetine

  2012cites this paper
• Эффективность паксила при лечении депрессий у мужчин пожилого возраста

  2012cites this paper
• Role of Repetitive Transcranial Magnetic Stimulation in Maintenance Treatment of Resistant Depression

  2012cites this paper
• Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of Depression

  2012cites this paper
• Drug Class Review: Second-Generation Antidepressants

  2011cites this paper
• Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.

  2011cites this paper
• Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder

  2010influential citation
• Differences in clinical effect and tolerance between fluvoxamine and paroxetine: A switching study in patients with depression

  2010cites this paper
• Prediction of response within the first 3 days to treatment with paroxetine for depression.

  2008influential citation
• Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians

  2008cites this paper
• Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports

  2007influential citation
• Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.

  2007cites this paper
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.

  2007cites this paper
• Side effects of antidepressants: an overview.

  2006cites this paper
• The Cost of Depression and the Cost-Effectiveness of Pharmacological Treatment

  2006cites this paper
• [Difficulties in the diagnosis and treatment of major depressive disorder with comorbid anxiety symptoms].

  2006cites this paper
• WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).

  2006cites this paper
• WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression.

  2006cites this paper
• Side effects of antidepressants : An overview

  2006cites this paper
• Adverse effects of antidepressant drugs , based on mechanism of action

  2006cites this paper
• Anksiyete Belirtilerinin Eşlik Ettiği Majör Depresif Bozukluğun Tanı ve

  2006cites this paper
• Excessive daytime sleepiness in psychiatry: a relevant focus for clinical attention and treatment?

  2006cites this paper
• Common Methodological Flaws in Economic Evaluations

  2005cites this paper
• Newer v. older antidepressants in long-term pharmacotherapy: Revisiting... Prevention of relapse and recurrence of depression

  2005cites this paper
• Are SSRIs really more effective for anxious depression?

  2005cites this paper
• [Rexetin in the therapy of depressive states].

  2005cites this paper
• Symptom dimensions of depression over the course of treatment : an application of the tripartite model.

  2005cites this paper
• Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation

  2004cites this paper
• Pharmacoeconomic evaluations and primary care prescribing

  2004cites this paper
• Current Role of Herbal Preparations

  2004cites this paper
• Antisuicide Properties of Psychotropic Drugs: A Critical Review

  2004cites this paper
• Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials

  2003cites this paper
• [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].

  2003cites this paper
• In search for more confidence in health economic modelling : reducing uncertainty associated with modelling studies

  2003cites this paper
• Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

  2003cites this paper
• How can research ethics committees protect patients better?

  2003cites this paper
• The effect of alexithymic features on response to antidepressant medication in patients with major depression

  2003cites this paper
• Antidepressant-induced hepatotoxicity.

  2003cites this paper
• A reevaluation of the exclusion criteria used in antidepressant efficacy trials.

  2002cites this paper
• Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.

  2002cites this paper
• Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor depression

  2002cites this paper
• Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

  2002cites this paper
• Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

  2002cites this paper
• Improved sample preparation for the quantitative analysis of paroxetine in human plasma by stable isotope dilution negative ion chemical ionisation gas chromatography-mass spectrometry.

  2002cites this paper
• Paroxetineof Its Use in Psychiatric Disorders in Adults

  2002cites this paper
• Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.

  2002cites this paper
• The prescribing of psychotropic drugs in mental health services in Trinidad.

  2002cites this paper
• Spotlight on Paroxetine in Psychiatric Disorders in Adults

  2002cites this paper
• Antidepressant-induced hepatotoxicity

  2002cites this paper
• Paroxetine: an update of its use in psychiatric disorders in adults.

  2002cites this paper
• Enhancing the Technology of Clinical Trials and the Trials Model to Evaluate Newly Developed, Targeted Antidepressants

  2002cites this paper
• [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].

  2002cites this paper
• Assessment of clinical guidelines for continuation treatment in major depression.

  2001cites this paper
• Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.

  2001cites this paper
• Stable isotope dilution negative ion chemical ionization gas chromatography-mass spectrometry for the quantitative analysis of paroxetine in human plasma.

  2001cites this paper
• Clinical Guidelines for the Treatment of Depressive Disorders IV. Medications and Other Biological Treatments

  2001cites this paper
• Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients

  2001cites this paper
• Effects of fluvoxamine on morphine-induced inhibition of gastrointestinal transit, antinociception and hyperlocomotion in mice.

  2001cites this paper
• Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.

  2001cites this paper
• Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline

  2001cites this paper
• Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

  2001influential citation
• ADHD comorbidity findings from the MTA study: comparing comorbid subgroups.

  2001cites this paper
• Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.

  2000cites this paper
• Latency to paroxetine‐induced anxiolysis in the rat is reduced by co‐administration of the 5‐HT1A receptor antagonist WAY100635

  2000cites this paper
• Does placebo help establish equivalence in trials of new antidepressants?

  2000cites this paper
• Comparative efficacy of antidepressants on anxiety features in depression: A meta-analysis of double-blind studies of imipramine and moclobemide against placebo

  2000cites this paper
• A Critical Review of Published Economic Modelling Studies in Depression

  2000cites this paper
• The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared.

  2000cites this paper
• Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

  2000cites this paper
• SSRIs versus other antidepressants for depressive disorder.

  2000cites this paper
• Una comparación doble ciego de sertralina y fluoxetina en el tratamiento de episodio depresivo mayor en pacientes ambulatorios

  1999cites this paper
• The role of depression in coronary artery disease.

  1999cites this paper
• Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

  1999cites this paper
• Rational decision-making in mental health: the role of systematic reviews.

  1999cites this paper
• Paroxetine

  1999cites this paper
• Depression in breast cancer patients: the need for treatment.

  1999cites this paper
• [Motor signs of depression].

  1999cites this paper
• Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology.

  1999cites this paper
• Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology.

  1999cites this paper
• [Sexual dysfunction with antidepressive agents. Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRI].

  1999cites this paper
• Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.

  1999cites this paper
• The use of meta-analysis in economic evaluation

  1999cites this paper
• Paroxetine and its uses in psychiatry.

  1999cites this paper